BioCentury on BioBusiness,
Tools & Techniques
Other RA players speak up
Monday, November 17, 1997
Compounds targeting tumor necrosis factor alpha (TNF-a), specifically Immunex Corp.'s Enbrel and Centocor Inc.'s Avakine, are leading the pack as the potential new gold standard for rheumatoid arthritis treatment (see BioCentury, Nov. 10). Among products coming up behind Enbrel and Avakine are two peptide vaccines that could have utility by acting upstream and preventing the activation of the damaging T cells that lead to production of TNF and inflammation.
The Immune Response Corp. presented Phase II data with its IR501 T cell receptor (TCR) peptide vaccine, and Anergen Inc. last week presented Phase II data with its AnervaX HLA-DR4/1 haplotype-specific MHC class II peptide vaccine at the American College of Rheumatology meeting in Washington.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]